Leucovorin (Calcium Folinate Pentahydrate)

Calcium Folinate, the active form of folinic acid, bypasses the dihydrofolate reductase step and directly enters the folate cycle. This restores tetrahydrofolate pools, enabling DNA synthesis and repair in healthy cells, thereby counteracting the inhibition caused by antifolate drugs such as methotrexate.

The dose of Leucovorin is individualized and must be prescribed by a qualified healthcare professional. The prescriber determines the amount, frequency, and duration based on the specific indication, patient characteristics, and concurrent therapies.

Safety data for Leucovorin during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using this medication.

To order Leucovorin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Leucovorin (folinic acid) is a reduced folate that bypasses the enzymatic step blocked by antifolate drugs, whereas folic acid requires conversion by dihydrofolate reductase. This makes Leucovorin more effective for rescuing cells from methotrexate toxicity and for enhancing fluoropyrimidine activity, while standard folic acid is primarily used for general dietary supplementation.

Leucovorin should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. No refrigeration is required for the oral formulation.

Leucovorin is administered orally in tablet or liquid form, as directed by the prescribing clinician. The medication is taken with or without food, according to the specific dosing schedule provided, and should be swallowed whole unless a liquid formulation is prescribed.

Serious adverse reactions, although rare, include anaphylaxis, Stevens‑Johnson syndrome, severe hepatic or renal dysfunction, and pancytopenia. Patients should seek immediate medical attention if they experience symptoms such as difficulty breathing, widespread rash, jaundice, dark urine, or unexplained bruising or bleeding.

Leucovorin is contraindicated in individuals with known hypersensitivity to folinic acid or any of its excipients. Caution is also advised for patients with severe renal or hepatic impairment, and it should be avoided in combination with certain antifolate agents when rescue timing cannot be ensured.